OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a clinical-stage biotechnology company focused on antibody discovery, providing proprietary transgenic animal platforms that generate diverse antibody candidates for biopharmaceutical partners. The company went public in 2022 through a de-SPAC merger with Avista Public Acquisition Corp. II, a blank-check company sponsored by Avista Capital Partners, a healthcare-focused private equity firm. The February 2023 S-1/A filing represents a post-merger registration amendment reflecting ongoing capital markets activity following the transaction close. OmniAb operates in the life sciences tools and services sector, with its technology licensed to a broad network of pharmaceutical and biotechnology collaborators. For full filing history, deal terms, and sponsor data on OABI, sign up for SpacDesk.